JAKé»å®³è¬ã¯ããã¡ã·ãããïŒãŒã«ã€ã³ãïŒãããªã·ãããïŒãªã«ããšã³ãïŒãããã£ã·ãããïŒã¹ãã€ã©ãïŒããŠããã·ãããïŒãªã³ãŽã©ãã¯ïŒããã£ã«ãŽãããïŒãžã»ã¬ã«ïŒã®5çš®é¡ãçŸåšè²©å£²ãããŠããŸãã
æ·»ä»ææžãæ¯èŒããŠã¿ãŸããïŒéžææ§ã¯IC50å€ããå€æïŒã
ããã¡ã·ããããšãŠããã·ãããã¯äœµçšè¬ã«æ³šæãå¿ èŠã§ãããªã·ãããã¯è é害ã«æ³šæãå¿ èŠã§ãã垯ç¶ç±ç¹ãå€ããšããã®ãJAKé»å®³è¬ã®ç¹åŸŽã§ãããããã£ã·ãããã®å¯äœçšã矀ãæããŠå€ããããã¯åŸè¿°ããããã«JAK2éžææ§äœãã«ãé¢ããã貧è¡ãå€ããææšèšå®ãäœãéãã®ããç¥ããŸãããããã§æè¿ã®ã¡ã¿è§£æãèªãã§ã¿ãŸããã
ã¡ã¿è§£æã®çµæã玹ä»ããåã«ããŸãã¯åºç€çãªè©±ã§ããé»å®³ãããJAKã®ãµãã¿ã€ãïŒJAK1ãJAK2ãJAK3ãTYK2ïŒã«ãã£ãŠé¢é£ãããµã€ãã«ã€ã³ãç°ãªãè¬å¹ã¯ç°ãªããšäºæž¬ãããŸããããŸã èšåºçãªå·®ç°ã¯ããããã£ãŠããŸããã
ãµã€ãã«ã€ã³ããã¿ããšIL-6ã¯JAK1ãšãJAK2ãšãTYK2ãšãé¢é£ããããå¹æã ããèããã°é»å®³ãããµãã¿ã€ããå€ãã»ããæççå¹æã¯æåŸ ã§ãããã§ãã
JAK1ã现èæ§å ç«ãççããªã³ãçååãæãŠã€ã«ã¹äœçšå šè¬ã«é¢ããäžå¿çãªåœ¹å²ãæ ã£ãŠããŸããJAK2ã¯G-CSFãEPOãTPOãšé¢é£ããŠããé è¡ã«ãé¢ããã®ã§å¯äœçšãããã¡ã€ã«ã«æ³šæãå¿ èŠããã§ããTYK2ã¯IFNαãIFNβã«é¢é£ããããŠã€ã«ã¹æŽ»æ§åã«å·®ç°ãããããç¥ããŸããã
Biomolecules . 2020 Jul 5;10(7):1002.
æãå ±åãå€ãããã¡ã·ãããïŒãŒã«ã€ã³ãïŒãããªã·ãããïŒãªã«ããšã³ãïŒã®2å€ã®å¯äœçšãæ¯èŒããŠã¿ããšãJAK1,2,3ãé»å®³ããããã¡ã·ããããããJAK 1,2ã ããé»å®³ããããªã·ãããã®ã»ããJAK2éžææ§ãé«ããšãèšããè¡çå¯äœçšãå€ãããšã瀺ãããŠããŸããããã¯æ·»ä»ææžããã¯èªã¿åããŸããã§ããããã¯ãæ·»ä»ææžã ãèŠãŠããŠã¯ã ãã§ããã
å³ïŒBaricitinibãšTofacitinibå¯äœçšå ±åã«ãããæ¯çã(Biomolecules . 2020 Jul 5;10(7):1002.
ããããŒã¿äžéšæç²ãäœæã泚ïŒå ±åãããå¯äœçšã®ãã¡ã©ã®ãããªå¯äœçšãå€ãããæ¯èŒãããã®ã§ãå¯äœçšã®çºççãçŽæ¥æ¯èŒãããã®ã§ã¯ãªã)
ããã§ã¯èå¿ã®å¹æã®æ¯èŒã§ããããããã¯ãŒã¯ã¡ã¿è§£æã®å ±åããããŸãã(J Clin Pharm Ther . 2020 Aug;45(4):674-681.)ã
ACR20ãæ¯èŒããå¹æå€å®ã§ã¯ããã£ã·ããããæãå¹æãé«ãå¯èœæ§ãé«ãã£ãã§ããããããã¹ãŠã®JAKãééžæçã«é»å®³ããã ãã¯ããããšããããšã§ããããããã£ã«ãŽããããããã«ç¶ããŸãããã ãããã®è¬å€ã¯è«ææ°ãå°ãªããä»åŸã®ãšããã³ã¹ã®èç©ïŒç¹ã«çŽæ¥æ¯èŒã®ããŒã¿ïŒã«ãã£ãŠã¯ãã®çµæãèŠãããšã¯ãããããã§ãããŠããã·ããããããªã·ãããã®å¹æã¯åŒ±ãåŸåã«ãããããå¯äœçšãããã¡ã€ã«ãè¯ããªããã°ç©æ¥µçã«äœ¿ãçç±ã¯ãªãããã§ã(ããªã·ãããã¯èé害ã®ããæ£è ã«äœ¿ããããã®ã¯ãããŸãã)ã
å¯äœçšã®è§£æã§ã¯ããã¡ã·ãããã ããä»å€ã«åªäœæ§ã蚌æã§ããŸããã䜵çšè¬ã®åé¡ãã¯ãªã¢ã§ããã°ããã£ãšãå®å šã«äœ¿ããè¬å€ãšã¯èšãããã§ãããã ãã©ã»ãããå®å šãšããçµæã¯æ°åã®ããžãã¯ã§ãããã
SUCRAãã°ã©ãåããŠã¿ãŸãããå³äžã®è¬å€ã»ã©åªããè¬å€ã§ãããŸããããã®ããŒã¿ã¯3ïŒ6ãæãã芳å¯æéããªãããšã«æ³šæããŠãã ããã
ããšã¯ããã€ãè足ã§ã(å³è¡šã¯Immunotherapy . 2019 Jun;11(8):737-754.ãã)ã
ããã¡ã·ãããã¯5mgã§ã¯ãªã10mgã®æ¹ãå¹æãé«ãã朰çæ§å€§è žçã§ã¯äžå®ã®æ¡ä»¶äžã§ã¯10mg BIDãèªããããŠãããMTX䜵çšäžã§ã¯ADAãšå¹æåçã§ã¯ããããåå€ã§ã¯å¹æã¯å£ãã
ããªã·ãããã¯åã¢ã¡ãªã«ã§ã¯2mgã§ããèªå¯ãããŠããªãããã ã2mgãåå€ã§ãæ¯èŒçè¯ãæ瞟ã«æãããã2mgããèªå¯ãããŠããªãã®ã¯ã4mgæäžã§æ©åºäžæãªããæ·±éšéèè¡æ çãå ±åãããããïŒã ãšæãïŒãæ確ãªããŒã¿ã¯ä¹ãããã®ã®ãJAKé»å®³è¬æäžäžã¯æªæ§è «çãæ¶å管穿åãæ·±éšéèè¡æ çãé質æ§èºçã«ã€ããŠã¯é ã®çé ã«å ¥ããŠããæ¹ãè¯ããšæããŸãã
ããã£ã·ãããã¯æ¥æ¬åã®è¬å€ã®ãããããŒã¿ãå°ãªãã§ãããADAãšã®æ¯èŒããããŠããªãJAKé»å®³è¬ã§ãããããã£ãæå³ã§ã¯JAK 1stã§éžæãããè¬å€ã§ã¯ãªãããç¥ããŸããã䜵çšè¬ã®å¶éãã»ãšãã©ãªããè é害ããå Žåã«æã䜿ããããè¬å€ãšããããšã¯ãŠãªã§ãããã50mgã§ã¯å¹æä¹ããããšã«ãªã£ãŠããŸãããå°æãªé«éœ¢è ã§ã¯50mgé ã䜿ããšããéžæè¢ã¯ããããç¥ããŸããã
ãŠããã·ãããã¯ãã®åŸRCTã§å¹æãADAããåããšããå ±åãã§ãŠããŸã(Arthritis Rheumatol . 2019 Nov;71(11):1788-1800.)ã也ç¬æ§é¢ç¯çïŒé¢ç¯çæ§ä¹Ÿç¬ïŒãšã¢ãããŒæ§ç®èçã«è¿œå æ¿èªãç³è«ããŠããŸãã
ãã£ã«ãŽãããã¯2020幎9æçºå£²ã®ãã£ãšãæ°ããJAKé»å®³è¬ã§ããJAK1,2ã«éžææ§ãé«ããšããç¹åŸŽã§éžã¶ãªããè é害ããã°ãŠããã·ããããèé害ãããã°ããªã·ãããã䜵çšè¬ãæ°ã«ããã°ãã£ã«ãŽããããšãã䜿ãåãã¯ããããç¥ããŸãããè£ãã¿ã«ã€ããŠã¯ãŸã äœãç¥ããŸããã